News

Rivaroxaban monitoring kit launched in Europe


 

Rivaroxaban (Xarelto) tablets

Instrumentation Laboratory, a company that develops in vitro diagnostic instruments, has announced the commercialization of the HemosIL Rivaroxaban Testing Solution in Europe.

This testing kit consists of the HemosIL Liquid Anti-Xa Assay, Rivaroxaban Calibrators, and Rivaroxaban Controls, which can be used with ACL TOP Hemostasis Testing Systems to monitor patients taking the oral anticoagulant rivaroxaban (Xarelto).

The assay, calibrators, and controls are now CE IVD Marked under the European IVD Directive 98/79/EC.

This allows Instrumentation Laboratory to distribute the HemosIL Rivaroxaban Testing Solution in the European Union and other international territories.

Although monitoring is generally not required for patients on rivaroxaban, there are cases in which measuring rivaroxaban may be necessary.

This includes patients who present with bleeding, require reversal of anticoagulation, experience deteriorating renal function, or must undergo surgery or an invasive procedure and have taken rivaroxaban within 24 hours or longer if creatinine clearance is < 50 mL min-1.

Liquid Anti-Xa Assay

The HemosIL Liquid Anti-Xa kit is a one-stage chromogenic assay based on a synthetic chromogenic substrate and factor Xa inactivation. Rivaroxaban levels in patient plasma are measured automatically on an ACL TOP Hemostasis Testing System when this assay is calibrated with the HemosIL Rivaroxaban Calibrators.

The Anti-Xa Assay kit consists of:

  • Factor Xa reagent: 5 x 2.5 mL vial of a liquid preparation containing purified bovine factor Xa (approximately 5.5 nkat/mL), Tris-Buffer, EDTA, dextran sulfate, sodium chloride, and bovine serum albumin.
  • Chromogenic substrate: 5 x 3 mL vial of liquid chromogenic substrate S-2732 (approximately 1.2 mg/mL) and bulking agent.

Rivaroxaban Calibrators

The HemosIL Rivaroxaban Calibrators are intended for the calibration of the Liquid Anti-Xa Assay when testing for rivaroxaban on an ACL TOP Hemostasis Testing System.

Two levels of lyophilized calibrators prepared from human citrated plasma by means of a dedicated process at 2 different concentrations of rivaroxaban are used by the instrument to automatically prepare a calibration curve.

The Rivaroxaban Calibrator kit consists of:

  • Rivaroxaban Calibrator 1: 5 x 1 mL vials of a lyophilized human plasma containing buffers and stabilizers.
  • Rivaroxaban Calibrator 2: 5 x 1 mL vials of a lyophilized human plasma containing rivaroxaban, buffers, and stabilizers.

Rivaroxaban Controls

HemosIL Rivaroxaban Controls are intended for the quality control of the Liquid Anti-Xa Assay when testing for rivaroxaban on an ACL TOP Hemostasis Testing System.

Two levels of lyophilized controls are prepared from human citrated plasma by means of a dedicated process at 2 different concentrations of rivaroxaban. Use of both controls is recommended for a complete quality control program.

The Rivaroxaban Controls kit consists of:

  • Rivaroxaban Low Control: 5 x 1 mL vials of a lyophilized human plasma containing rivaroxaban, stabilizers, and buffer solution.
  • Rivaroxaban High Control: 5 x 1 mL vials of a lyophilized human plasma containing rivaroxaban, stabilizers, and buffer solution.

Recommended Reading

Esophagogastric cancer chemotherapy commonly causes VTE
MDedge Hematology and Oncology
NICE recommends edoxaban for NVAF
MDedge Hematology and Oncology
Education doesn’t ensure appropriate use of VTE prophylaxis
MDedge Hematology and Oncology
Drug on fast track to treat aHUS
MDedge Hematology and Oncology
FDA grants drug orphan designation for ITP
MDedge Hematology and Oncology
Nanocapsules exploit biology to destroy blood clots
MDedge Hematology and Oncology
DAPT may be better for older patients after PCI
MDedge Hematology and Oncology
Group creates vascular graft that resists thrombosis
MDedge Hematology and Oncology
Recombinant vWF can safely halt bleeding in vWD
MDedge Hematology and Oncology
Hemophilia A drug appears safe, effective long-term
MDedge Hematology and Oncology